2002
DOI: 10.1016/s1471-4922(01)02211-5
|View full text |Cite
|
Sign up to set email alerts
|

Towards a recombinant antigen vaccine against Onchocerca volvulus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
52
0
1

Year Published

2005
2005
2022
2022

Publication Types

Select...
5
4
1

Relationship

2
8

Authors

Journals

citations
Cited by 77 publications
(54 citation statements)
references
References 54 publications
1
52
0
1
Order By: Relevance
“…This evidence indicates the unique immunological characteristics of irradiated L 3 and strongly supports the feasibility of immunoprophylaxis against Onchocerca spp. However, because irradiated L 3 could never be used in humans because of constraints on mass production, stability, and safety, the next step is to reproduce significant protection using defined antigens (47).…”
Section: Discussionmentioning
confidence: 99%
“…This evidence indicates the unique immunological characteristics of irradiated L 3 and strongly supports the feasibility of immunoprophylaxis against Onchocerca spp. However, because irradiated L 3 could never be used in humans because of constraints on mass production, stability, and safety, the next step is to reproduce significant protection using defined antigens (47).…”
Section: Discussionmentioning
confidence: 99%
“…Currently, one larval antigen is being evaluated in a phase 1 clinical trial in a region of Brazil that is endemic for hookworm and a second adult hookworm antigen is about to enter into clinical trials (170). Related antigens are also being used to develop recombinant onchocerciasis vaccines (171). In addition, the Institut Pasteur is conducting clinical trials in sub-Saharan Africa using a recombinant vaccine (encoding a glutathione S-transferase) to protect against infection with S. haematobium (172).…”
Section: Global Control Of Helminthiases and Clinical Research Imperamentioning
confidence: 99%
“…Recombinant antigen vaccines against helminth infections have been tested with limited success (8,28,35,36), which in part may be due to the altered conformation and/or glycosylation of the recombinant antigens. An alternative vaccination approach has been to immunize mice with DNA, where the protein product is produced in vivo from the plasmid DNA.…”
mentioning
confidence: 99%